Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease
- PMID: 28102756
- PMCID: PMC5479399
- DOI: 10.1080/19490976.2017.1279377
Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease
Abstract
We recently compared results of fecal microbiota transplantation (FMT) in patients with refractory, recurrent Clostridium difficile infection (rCDI), with and without underlying inflammatory bowel disease (IBD). Here we extend this cohort and analyze outcomes in greater detail by subtype of IBD. We find that FMT is generally effective in breaking the cycle of CDI recurrence, but its effects on overall IBD progression are much less predictable. We discuss several challenges intrinsic to this complex clinical situation and outline the next steps that can address these challenges going forward.
Keywords: Crohn's disease; clostridium difficile; fecal microbiota transplantation; inflammatory bowel disease; ulcerative colitis.
Similar articles
-
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8. doi: 10.1016/j.cgh.2016.02.018. Epub 2016 Feb 22. Clin Gastroenterol Hepatol. 2016. PMID: 26905904 Free PMC article.
-
Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease.Gut Microbes. 2017 May 4;8(3):238-252. doi: 10.1080/19490976.2017.1290757. Epub 2017 Feb 10. Gut Microbes. 2017. PMID: 28609251 Free PMC article. Review.
-
Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center.Gut Microbes. 2021 Jan-Dec;13(1):1994834. doi: 10.1080/19490976.2021.1994834. Gut Microbes. 2021. PMID: 34709989 Free PMC article. Clinical Trial.
-
The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future.Inflamm Bowel Dis. 2017 Oct;23(10):1710-1717. doi: 10.1097/MIB.0000000000001247. Inflamm Bowel Dis. 2017. PMID: 28858073 Review.
-
Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.Dig Dis Sci. 2017 Oct;62(10):2870-2875. doi: 10.1007/s10620-017-4580-4. Epub 2017 Apr 27. Dig Dis Sci. 2017. PMID: 28451916
Cited by
-
Fecal microbiota transplantation cured epilepsy in a case with Crohn's disease: The first report.World J Gastroenterol. 2017 May 21;23(19):3565-3568. doi: 10.3748/wjg.v23.i19.3565. World J Gastroenterol. 2017. PMID: 28596693 Free PMC article.
-
Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease.J Inflamm Res. 2020 Sep 18;13:563-570. doi: 10.2147/JIR.S265520. eCollection 2020. J Inflamm Res. 2020. PMID: 32982371 Free PMC article.
-
The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease.Curr Opin Pharmacol. 2020 Dec;55:8-16. doi: 10.1016/j.coph.2020.08.009. Epub 2020 Oct 7. Curr Opin Pharmacol. 2020. PMID: 33035780 Free PMC article. Review.
-
Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies.Ann Gastroenterol. 2021 Nov-Dec;34(6):802-814. doi: 10.20524/aog.2021.0655. Epub 2021 Jul 2. Ann Gastroenterol. 2021. PMID: 34815646 Free PMC article.
-
Changes of intestinal microbiota and microbiota-based treatments in IBD.Arch Microbiol. 2022 Jul 1;204(7):442. doi: 10.1007/s00203-022-03069-4. Arch Microbiol. 2022. PMID: 35776212 Review.
References
-
- Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009; 104:1162-9; PMID: 19319128; http://dx.doi.org/10.1038/ajg.2009.4 - DOI - PubMed
-
- Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, et al.. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010; 4:194-8; PMID: 21122505; http://dx.doi.org/10.1016/j.crohns.2009.11.001 - DOI - PubMed
-
- Wadhwa A, Al Nahhas MF, Dierkhising RA, Patel R, Kashyap P, Pardi DS, Khanna S, Grover M. High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Ther 2016; 44:576-82; PMID: 27444134; http://dx.doi.org/10.1111/apt.13737 - DOI - PMC - PubMed
-
- Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, et al.. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571-607; PMID: 21464096; http://dx.doi.org/10.1136/gut.2010.224154 - DOI - PubMed
-
- Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, Mamula P, Baldassano RN. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:50-5; PMID: 20722068; http://dx.doi.org/10.1002/ibd.21421 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources